Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Perrie Ryan (NPI 1073530432)

Field	Value
Entity Type	Individual
Organization	Perrie Ryan
Address	222 E Medical Ln Ste 400
City	West Columbia
State	SC
ZIP	29169
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 15, 2006

Payer Source	Total Paid
Medicare	$3.3M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-only biller: lifetime Medicare revenue is $3.3M while Medicaid is reported as none (no Medicaid billing on file), indicating a single-payer footprint for public programs rather than a mixed Medicare/Medicaid panel. The NPI was enumerated 2006-07-15 (~20 years ago), so this is an established practice with roughly two decades of Medicare presence.

Revenue is highly concentrated in a small set of infusion drugs: the precomputed top-3 Medicare codes account for 45.1% of total Medicare revenue, driven by J9271 ($752K, 23.7%), J9299 ($422.4K, 13.3%), and J9173 ($258.5K, 8.1%). This concentration signals that a few high-cost oncology therapies constitute nearly half of the provider’s Medicare receipts.

The code mix identifies a specialty oncology infusion practice focused on immune checkpoint inhibitors and other biologics: top codes include J9271 (pembrolizumab), J9299 (nivolumab), J9173 (durvalumab), and multiple monoclonal antibody agents such as J9144 and J9312 alongside chemotherapy administration code 96413. Presence of administration codes and high-count injectables suggests the practice operates an on-site infusion suite providing ongoing IV oncology therapies.

Imaging and diagnostic PET utilization is a meaningful secondary service line: A9595 (piflufolastat f-18) generated $225.1K (7.1%) and 78815 (PET/CT fusion) generated $136.8K (4.3%), with A9552 also present at $28.9K (0.9%). These entries indicate integrated diagnostic staging and theranostic workflows supporting treatment decisions rather than purely office-based consultations.

Competitive standing is mixed across codes: for principal immune therapies the provider ranks in typical national ranges (J9271: #461 of 1841, 74th percentile; J9299: #199 of 505, 61th percentile; J9173: #27 of 53, 50th percentile) which suggests neither national dominance nor marginality for those agents. By contrast, some agents are clear outliers versus peers—J9035 (bevacizumab) ranks #15 of 1852 (99th percentile, notably above typical national volume)—indicating selective strength in specific biologic usage.

Several supportive-care and administration items are unusually high versus peers, reinforcing substantial infusion throughput: J2506 (pegfilgrastim) ranks #24 of 586 (96th percentile; notably above typical national volume) and 96413 ranks #402 of 7514 (95th percentile; notably above typical national volume). Additional high-percentile codes such as J0897 (denosumab) at the 91th percentile further point to above-typical utilization of supportive and bone-modifying agents.

The billing profile mixes very high-count, low-dollar supply codes alongside high-cost specialty drugs: for example J1439 shows 40.5K claims at $1 avg for $40.5K revenue, while immunotherapies show large dollar revenue per claim (e.g., J9271 at $752K). This pattern is consistent with an infusion clinic that bills many routine supply or injection items in volume while deriving substantial revenue from a smaller number of costly biologic agents.

For payers evaluating network exposure, the practice represents concentrated Medicare risk tied to high-cost oncology biologics and PET diagnostics; absence of Medicaid billing (none (no Medicaid billing on file)) simplifies payer mix but concentrates utilization variability in Medicare. Given the provider’s ~20-year Medicare tenure and the mix of typical and notably above-typical code ranks, contracting or utilization management should focus on the handful of agents that drive most revenue and the high-percentile biologics where this provider diverges from peers.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

95 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	18,800	$40	$752K
J9299	Injection, nivolumab, 1 mg	17,600	$20	$422.4K
J9173	Injection, durvalumab, 10 mg	4,170	$60	$258.5K
A9595	Piflufolastat f-18, diagnostic, 1 millicurie	480	$470	$225.1K
J9022	Injection, atezolizumab, 10 mg	3,430	$60	$219.6K
J0897	Injection, denosumab, 1 mg	11,760	$20	$211.7K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	6,300	$30	$201.6K
J9312	Injection, rituximab, 10 mg	2,220	$60	$142.1K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	190	$710	$136.8K
J9035	Injection, bevacizumab, 10 mg	2,120	$60	$118.6K

Showing 1–10 of 95

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 95 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

Perrie Ryan — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

95 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	18	30	19,700	$40	$832K
J9299	5	10	15,760	$20	$432K
J9144	10	10	8,460	$40	$349.4K
J9173	2	10	3,050	$60	$275.9K
J9022	3	10	3,550	$60	$239.1K
J9312	13	20	2,340	$60	$193.7K
A9595	3	10	410	$460	$175.9K
J0897	30	250	2,400	$20	$91.2K
J2506	3	10	740	$80	$55.9K
J1439	19	30	42,750	$1	$42.3K

Showing 1–10 of 95

Related Providers

Other providers that share a Tax Identification Number (TIN) with Perrie Ryan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Lexington Health Inc	SC	General Acute Care Hospital	$0	$27.4M
Lexington County Health Services District Inc	SC	General Acute Care Hospital	$0	$19.2M
Lexington Health Inc	SC	Urgent Care Clinic/Center	$0	$8.7M
Lexington Health Inc	SC	Pediatric Adolescent Medicine Physician	$0	$5.7M
Lexington Health Inc	SC	Emergency Medicine Physician	$0	$4.2M
Lexington County Health Serv	SC	General Acute Care Hospital	$0	$4M
Steven Madden	SC	Hematology & Oncology Physician	$4M	$0
Lexington Health Inc	SC	Family Medicine Physician	$0	$4M
Lexington Health Inc	SC	Obstetrics & Gynecology Physician	$0	$3.5M
Vijaya Korrapati	SC	Hematology & Oncology Physician	$3.4M	$0

Nearby Providers

Other providers in the same ZIP code as Perrie Ryan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Palmetto Infusion Services LLC	SC	Infusion Therapy Clinic/Center	$0	$93.6M
United Cerebral Palsy Of South Carolina, Inc	SC	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$15.7M
Palmetto Retina Center LLC	SC	Ophthalmology Physician	$0	$10.6M
Karen Park Family Dentistry, P.A.	SC	Dentist	$0	$4.2M
John Payne	SC	Ophthalmology Physician	$4M	$0
John Wells	SC	Ophthalmology Physician	$3.9M	$0
Lexington Treatment Specialists LLC	SC	Methadone Clinic	$76.7K	$3.6M
William Clark	SC	Ophthalmology Physician	$3.3M	$0
Asheesh Lal	SC	Hematology & Oncology Physician	$3.2M	$0
James Wells	SC	Hematology & Oncology Physician	$3.2M	$0

Perrie Ryan — Billing Profile & Reimbursement Data

Sign up for Perrie Ryan — Billing Profile & Reimbursement Data policy alerts

Perrie Ryan — Billing Profile & Reimbursement Data

Sign up for Perrie Ryan — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References